DSP106

//DSP106
DSP106 2018-04-29T11:01:18+00:00

DSP106
(PD1-CD70)

Discovery
KAHR-106-PD1-CD70

Targeted immune activation leading to T-cell mediated tumor destruction

  • PD-L1 is highly expressed on cancer cells and in the tumor microenvironment, allowing tumors to evade the immune system
  • CD27:CD70 interaction provides an immune stimulatory signal
  • DSP106 targets PD-L1 expressing tumor cells by blocking the corresponding immune checkpoint inhibitory signals while simultaneously activating the immune cells via the CD27:CD70 pathway

DSP106 PD1-CD70: Mechanism of Action

PD1-CD70 DSP target PD-L1 expressing tumors, simultaneously delivering an immune stimulatory signal and blocking immune inhibitory signals

PD1-CD70-DSP-target-PD-L1
MOA & in-vivo efficacy

MOA & in-vivo efficacy

  • DSP106 targets PD-L1 expressing tumors, simultaneously delivering an immune stimulatory signal and blocking immune inhibitory signals
  • Efficiently binds its targets PDL1 and CD27 in-vitro and on cells
  • Effectively activates CD70 signaling
  • Activates T cells in the presence of PD-L1 to secrete IFN-γ
  • Efficacy shown in 2 mouse cancer models
CMC development

CMC development

  • CMC development of the human protein initiated
Toxicology: mouse & monkey studies

Clinical development

  • Potential as a therapeutic agent and/or as an ex-vivo treatment to support adoptive T-cell therapy is being evaluated